GET DAILY SIGNALSSensus Healthcare (SRTS) Delivers Q3 2026 Results: Revenue Down 12.9% but Gross Profit Rises 21.2%
Key Takeaways
- Third-quarter 2026 revenue came in at $6.0 million, down 12.9% year over year and modestly below consensus estimates of about $6.2 million.
- Gross profit rose 21.2% to $3.3 million, reflecting improved margin performance even as top-line sales declined.
- The company posted a net loss of $1.4 million, or $0.09 per diluted share, in line with analyst expectations for the quarter.
- Operating loss narrowed to $1.6 million, and Sensus ended the period with $12.9 million in cash and cash equivalents.
- New reimbursement codes for superficial radiotherapy (SRT) treatments, effective January 2026, remain a key catalyst driving renewed customer activity.
- For more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for SRTS.
- To discover AI-driven trading ideas across the broader market, explore Trending AI Robots.
Earnings Context and Its Significance
Sensus Healthcare's quarterly results carry particular importance right now as the company works through a commercial shift. The medical device firm, which offers non-invasive superficial radiotherapy systems for skin cancer and keloids, has been moving away from reliance on one large historical customer and toward recurring rental and "Fair Deal Agreement" revenue. The new Current Procedural Terminology codes introduced in January 2026 have clarified reimbursement for physicians and are seen as a potential turning point for broader SRT use. This report provides an early read on whether commercial progress is beginning to show up in the numbers after a difficult first half of 2026.
Quarterly Performance Breakdown
In the third quarter of 2026, SRTS reported revenue of $6.0 million, a 12.9% drop from $6.88 million a year earlier and a bit below the consensus figure of roughly $6.2 million. The decline stems mainly from fewer system sales to the company's largest prior customer, though recurring and international placements helped offset some of the shortfall.
Gross profit climbed to $3.3 million, a 21.2% increase from $2.7 million last year, thanks to a more favorable revenue mix that supported higher margins. The operating loss narrowed to $1.6 million. Net loss totaled $1.4 million, or $0.09 per diluted share, matching analyst forecasts and improving from the larger loss seen earlier in the year.
The balance sheet showed $12.9 million in cash and cash equivalents at quarter end, with total liabilities falling to $5.1 million. Management continues to point to a stronger second half supported by an expanding pipeline and the booking of previously delayed unit sales. I also checked this using Tickeron’s AI Screener to see how SRTS compares to peers in the medical device space.
Investor Reaction and Current Sentiment
Market sentiment toward SRTS has stayed measured yet more stable lately. The stock has moved within a wide range over the past year amid questions about the speed of the customer transition and the timing of any SRT adoption pickup. Analysts had lowered near-term estimates ahead of the report, reflecting expectations of a transitional quarter.
The in-line net loss, along with sequential revenue improvement and better gross margins, indicates investors are now focusing more on signs that reimbursement-driven demand is building rather than fixating solely on the year-over-year revenue dip. A clean balance sheet and solid cash position have helped limit downside pressure.
What to Watch Going Forward
The key question remains whether the second half of 2026 can produce consistent sequential gains. Management has highlighted a stronger commercial pipeline tied to physician education on the new CPT codes. Several areas deserve close attention in the coming quarters.
First, track the pace of SRT system placements and the balance between outright sales and recurring rental or Fair Deal structures. A growing recurring base should add visibility but may weigh on near-term revenue recognition.
Second, monitor gross margin trends. The improvement seen this quarter points to better mix and cost control, and sustaining that will be important for further narrowing operating losses.
Third, follow international growth and the rollout of the software platform, which management sees as a higher-margin recurring stream. Finally, keep an eye on cash burn and inventory levels, which have increased in anticipation of demand. These will help gauge whether the company can reach profitability without raising additional capital. I ran a quick scan with Tickeron’s AI Trend Prediction Engine to gauge potential momentum signals in the healthcare sector.
My Take on Tickeron AI Tools for Research
When analyzing names like SRTS, I often turn to Tickeron’s AI Daily Buy/Sell Signals to cross-check technical setups against fundamentals. The platform helps surface comparable opportunities and emerging patterns across the medical device landscape in a structured way that saves time compared with manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRTS in upward trend: 10-day moving average moved above 50-day moving average on November 11, 2026
The 10-day moving average for SRTS crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SRTS as a result. In 82 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for SRTS just turned positive on November 03, 2026. Looking at past instances where SRTS's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.
SRTS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 222 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for SRTS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SRTS broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (4.142). P/E Ratio (-3.043) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. SRTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of skin cancer treatment products
Industry MedicalNursingServices
Advertisement